2,3-bis(chloromethyl)-1,4-naphthoquinone
structure
Networked: 2
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Neoplasms (Cancer)
|
2. | Sarcoma 180
01/01/1979
- " Effects of the bioreductive alkylating agent 2,3-bis(chloromethyl)-1,4-naphthoquinone on coupled mitochondria isolated from sarcoma 180 ascites cells." 11/01/1976
- " The bioreductive alkylating agent, 2,3-bis(chloromethyl)-1,4-napthoquinone (CMNQ), has been shown to inhibit the growth of Sarcoma 180 ascites cells in vivo. " 11/01/1976
- " This action was due to (a) a drug-induced decrease in intracellular levels of adenosine 5'-triphosphate, presumably resulting from uncoupling of oxidative phosphorylation by CMNQ; and (b) a partial loss of thymidine kinase activity in Sarcoma 180 cells, which did not appear to be due to direct inhibition of the enzyme by the drug. " 11/01/1976
- " Consistent with the concept that reduction of CMNQ to a hydroquinone results in the generation of an alkylating species (i.e., a quinone methide) was the finding that radioactivity from [14C]CMNQ present in Sarcoma 180 ascites cells was associated with DNA, RNA, and protein for a period of up to 72 hr after exposure to tumor-bearing animals to this agent. "
|
3. | Ascites
|
|
Related Drugs and Biologics